| 000 | 01698 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250516033514.0 | ||
| 264 | 0 | _c20111004 | |
| 008 | 201110s 0 0 eng d | ||
| 022 | _a1099-081X | ||
| 024 | 7 |
_a10.1002/bdd.754 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLee, Chong-Ki | |
| 245 | 0 | 0 |
_aEffects of oral curcumin on the pharmacokinetics of intravenous and oral etoposide in rats: possible role of intestinal CYP3A and P-gp inhibition by curcumin. _h[electronic resource] |
| 260 |
_bBiopharmaceutics & drug disposition _cMay 2011 |
||
| 300 |
_a245-51 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aATP Binding Cassette Transporter, Subfamily B, Member 1 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xadministration & dosage |
| 650 | 0 | 4 |
_aCurcumin _xadministration & dosage |
| 650 | 0 | 4 |
_aCytochrome P-450 CYP3A _xphysiology |
| 650 | 0 | 4 | _aCytochrome P-450 CYP3A Inhibitors |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aEtoposide _xadministration & dosage |
| 650 | 0 | 4 |
_aFluorescent Dyes _xpharmacokinetics |
| 650 | 0 | 4 | _aInjections, Intravenous |
| 650 | 0 | 4 |
_aIntestinal Mucosa _xmetabolism |
| 650 | 0 | 4 |
_aIntestines _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Sprague-Dawley |
| 650 | 0 | 4 |
_aRhodamine 123 _xpharmacokinetics |
| 700 | 1 | _aKi, Sung-Hwan | |
| 700 | 1 | _aChoi, Jun-Shik | |
| 773 | 0 |
_tBiopharmaceutics & drug disposition _gvol. 32 _gno. 4 _gp. 245-51 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/bdd.754 _zAvailable from publisher's website |
| 999 |
_c20771724 _d20771724 |
||